These programs are often referred to as accumulator adjustment programs. Patients with these plan limitations are not eligible for the AVSOLA® Co-Pay Card but may be eligible for other needs-based assistance provided by Amgen. The AVSOLA® Co-Pay Card does not cover out-of-pocket costs for any patient whose selected coverage option under their commercial insurance plan does not apply AVSOLA® Co-Pay Card payments to satisfy the patient’s co-payment, deductible, or co-insurance for AVSOLA®.

A patient is considered cash-paying where the patient has no insurance coverage for AVSOLA® or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an AVSOLA® prescription. It is not valid for cash-paying patients or where prohibited by law. This offer is not valid for patients whose AVSOLA® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program.

There is no income requirement to participate in this program. The AVSOLA® Co-Pay Card does not cover any other costs related to office visits or administration of AVSOLA®. This program helps eligible patients cover out-of-pocket medication costs related to AVSOLA®, up to program limits. *Eligibility Criteria: Subject to program limitations and terms and conditions, the AVSOLA® Co-Pay Card is open to patients who have been prescribed AVSOLA® and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. Psoriatic Arthritis (PsA): Can reduce signs and symptoms of active arthritis, help stop further joint damage, and improve physical function in adult patients with PsAĪnkylosing Spondylitis (AS): Can reduce signs and symptoms in adult patients with active ASĬhronic Severe Plaque Psoriasis: Approved for the treatment of adult patients with severe (extensive and/or disabling) plaque psoriasis under the care of a physician who will determine if AVSOLA® is appropriate considering other available therapies Moderate to Severe Rheumatoid Arthritis (RA): Can reduce signs and symptoms, help stop further joint damage, and improve physical function in adult patients with moderately to severely active RA, in combination with methotrexate Moderate to Severe Pediatric Ulcerative Colitis: Can reduce signs and symptoms, and induce and maintain remission, in children (ages 6-17) with moderately to severely active ulcerative colitis who haven’t responded well to other therapies Moderate to Severe Ulcerative Colitis (UC): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active UC who haven’t responded well to other therapies Moderate to Severe Pediatric Crohn’s Disease: Can reduce signs and symptoms, and induce and maintain remission, in children (ages 6-17) with moderately to severely active Crohn’s disease who haven’t responded well to other therapies To learn more about available programs please call the appropriate hotline number from the list below.Moderate to Severe Crohn’s Disease: Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn’s disease who haven’t responded well to other therapies Amgen’s patient assistance programs provide a variety of support services for patient prescribed Amgen medications as well as financial support for qualifying patients who are uninsured or underinsured with limited financial resources.

Otezla copay card